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ABSTRACT
Bloodstream infection (BSI) is a significant problem after cord blood transplantation (CBT). However, little
information has been reported on BSI after reduced-intensity CBT (RI-CBT). We retrospectively reviewed
the medical records of 102 patients. The median age of the patients was 55 years (range, 17-79 years).
Preparative regimens comprised fludarabine 125 to 150 mg/m2, melphalan 80 to 140 mg/m2, or busulfan 8
mg/kg and total body irradiation 2 to 8 Gy. Prophylaxis against graft-versus-host disease comprised cyclosporin
or tacrolimus. BSI developed within 100 days of RI-CBT in 32 patients. The cumulative incidence of BSI was
25% at day 30 and 32% at day 100. The median onset was day 15 (range, 1-98 days). Causative organisms
included Pseudomonas aeruginosa (n  12), Staphylococcus epidermidis (n  11), Staphylococcus aureus (n  6),
Enterococcus faecium (n  4), Enterococcus faecalis (n  4), Stenotrophomonas maltophilia (n  4), and others
(n  7). Of the 32 patients with BSI, 25 (84%) died within 100 days after RI-CBT. BSI was the direct cause of
death in 8 patients (25%). Univariate analysis failed to identify any significant risk factors. BSI clearly
represents a significant and fatal complication after RI-CBT. Further studies are warranted to determine
clinical characteristics, identify patients at high risk of BSI, and establish therapeutic strategies.
© 2005 American Society for Blood and Marrow Transplantation
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Bacterial infection is a major cause of morbidity
nd mortality in neutropenic patients after cancer che-
otherapy. [1] Approximately half of febrile neutro-
enic patients have established or occult undiagnosed
nfection, and approximately 20% of patients with neu-
rophil counts of 0.1  109/L acquire bacteremia. [1]
he most common portal of bacterial infection is the
limentary tract, where cancer chemotherapy–induced
ucosal damage allows invasion by opportunistic or-
anisms. Similarly, damage to the skin integument by o
B&MTnvasive procedures, such as placement of vascular
ccess devices, provides portals of entry for infectious
rganisms.
The frequency of bacterial infection after alloge-
eic hematopoietic stem cell transplantation (allo-
CT) has decreased with the widespread use of anti-
icrobiotic prophylaxis and empirical administration
f broad-spectrum antimicrobiotics. However, better
ontrol of gram-negative infections in neutropenic
atients has fostered the increase of infections caused
y gram-positive organisms and also gram-negative
rganisms resistant to -lactams or ﬂuoroquinolones.
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4hese organisms now account for most bacterial in-
ections. [2-4] Despite improvements in supportive
easures, early bacterial infection remains a signiﬁ-
ant problem in both myeloablative and reduced-in-
ensity stem cell transplantation. [5,6]
Cord blood transplantation (CBT) is an attractive
lternative for patients with hematologic diseases in
he absence of matched related or unrelated donors.
he value of CBT with myeloablative preparative
egimens has been conﬁrmed for pediatric patients.
7,8] Myeloablative CBT for adult patients offers a
0% chance of engraftment with a 15% rate of trans-
lant-related mortality, mostly attributable to infec-
ion. [9-12] We and other groups recently reported
he feasibility of reduced-intensity CBT (RI-CBT)
egimens for adult patients with advanced hemato-
ogic diseases. [10,13-17]
Delayed immune recovery and graft-versus-host
isease (GVHD) contribute to infection being the
eading cause of transplant-related mortality after
BT with myeloablative preparative regimens.
8,11,12,17] However, studies on immune recovery
fter RI-CBT have produced optimism that RI-CBT
ecipients may experience less GVHD and fewer in-
ectious complications. Although RI-CBT is a prom-
sing treatment for patients with hematologic diseases,
ittle information has been reported on infectious
omplications after RI-CBT. We therefore retrospec-
ively investigated the frequency and clinical features
f bacteremia in patients who received RI-CBT for
dvanced hematologic disease.
ATIENTS AND METHODS
tudy Patients and Donors
Between January 2002 and March 2004, 102 pa-
ients with hematologic diseases or solid tumors un-
erwent RI-CBT at Toranomon Hospital, Japan. All
atients had diseases that were incurable with conven-
ional treatments and were considered inappropriate
or conventional allo-SCT because of the lack of an
LA-identical sibling or a suitable unrelated donor,
ge 50 years, and/or organ dysfunction (generally
ttributable to previous intense chemotherapy, radio-
herapy, or both). All patients provided written in-
ormed consent in accordance with the requirements
f the Institutional Review Board.
LA Typing and Donor Matching
A search for unrelated donors was performed by
sing the Japan Marrow Donation Program [18] for
atients without HLA-identical sibling donors. If no
ppropriate donor was identiﬁed, then the Japan Cord
lood Bank Network [19] was searched. A total of 54
atient/cord blood pairs were sex mismatched. Cord
lood units were not depleted of T lymphocytes.
30reparative Regimen
All patients received purine analog–based prepar-
tive regimens (Table 1).
ngraftment
Engraftment was deﬁned as white blood cell
ounts 1.0  109/L or absolute neutrophil counts
0.5  109/L for 2 consecutive days. Granulocyte
olony-stimulating factor (ﬁlgrastim or lenograstim)
as administered intravenously from day 1 until neu-
rophil engraftment.
upportive Care and Management of GVHD
All patients were managed in reverse isolation in
aminar airﬂow–equipped rooms and received tri-
ethoprim/sulfamethoxazole for prophylaxis against
neumocystis carinii. Fluoroquinolone and either ﬂu-
onazole or itraconazole were administered for pro-
hylaxis against bacterial and fungal infections, re-
pectively. Prophylaxis against herpesvirus infection
as also administered with acyclovir. [20] Neutro-
enic fever was managed according to the guidelines
or the use of antimicrobial agents in neutropenic
atients. [1,21] Cytomegalovirus (CMV) pp65 anti-
enemia was monitored on a weekly basis. If positive
esults were identiﬁed, preemptive therapy was initi-
ted with ganciclovir or foscarnet. Hemoglobin and
latelet counts were maintained at 7 g/dL and 10
109/L, respectively, by using in-line ﬁltered and
rradiated blood transfusions.
GVHD was clinically diagnosed in combination
ith skin or gut biopsies after engraftment or attain-
ent of 100% donor chimerism. Acute and chronic
VHD were graded according to established criteria.
22,23] GVHD prophylaxis involved continuous infu-
ion of cyclosporin 3 mg/kg or tacrolimus 0.03 mg/kg
rom day 1 until the patient tolerated oral adminis-
ration (Table 1). The dose was tapered from day 100
o day 150 or according to GVHD status. If grade II
o IV acute GVHD developed, prednisolone 1 mg/
g/d was added to cyclosporin or tacrolimus and ta-
ered from the beginning of the clinical response.
iagnosis and Definition of Bloodstream Infection
When febrile episodes occurred, multiple blood
ultures were obtained after the skin or catheter hub
as swabbed with 10% povidone-iodine. Bloodstream
nfection (BSI) must have met at least 1 of the follow-
ng criteria, [24] and bacteremia was deﬁned as the
ondition described in criterion 2.
riterion 1: patient had a recognized pathogen cul-
tured from 1 blood culture, and the organism
cultured from blood was unrelated to any infection
at another site.
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Bloodstream Infections after Umbilical Cord Blood Transplantation
Briterion 2: patient had 1 clinical symptom, such as
temperature 38°C, chills, or hypotension (sys-
tolic blood pressure90 mm Hg), and at least 1 of
the following:
. Common skin contaminant such as diphtheroids,
Bacillus species, Propionibacterium species, coagu-
lase-negative staphylococci, and micrococci, cul-
tured from 2 blood cultures drawn on separate
occasions.
. Common skin contaminant such as diphtheroids,
Bacillus species, Propionibacterium species, coagu-
lase-negative staphylococci, and micrococci, cul-
tured from 1 blood culture from a patient with
an intravascular line, for whom appropriate anti-
microbial therapy had been instituted.
Fevers associated with GVHD, engraftment syn-
rome, [25] pre-engraftment noninfectious fever, [16]
harmacotherapies, and primary malignancies were
iagnosed on the basis of a clearly documented clinical
istory and physical examination, without direct con-
able 1. Patient Characteristics in RI-CBT
Variable Data
ge, y, median (range) 55 (17–79)
ex (men/women) 55/47
rimary diseases
Acute lymphoblastic leukemia 13
Acute myeloid leukemia 29
Chronic myelogenous leukemia 1
Adult T-cell leukemia 14
Myelodysplastic syndrome 12
Malignant lymphoma 23
Multiple myeloma 4
Solid tumor 2
Aplastic anemia 4
isk of underlying deseases (high/
low) 77/25
reparative regimens
Flud 125 mg/m2  L-PAM (80-
140 mg/m2)  TBI (2-8 Gy) 92
Flud 150 mg/m2  BU 8 mg/kg 
TBI (4-8 Gy) 8
Flud 150 mg/m2  L-PAM 140
mg/m2 1
L-PAM 100 mg/m2 1*
umber of infused nuclear cells,
median (range) 2.9  107/kg (1.7–5.2)
umber of infused CD34 cells,
median (range) 0.77  105/kg (0.01–3.3)
VHD prophylaxis
Cyclosporine 88
Tacrolimus 14
lud indicates ﬂudarabine; L-PAM, melphalan; BU, busulfan; TBI,
total body irradiation; GVHD, graft-versus-host disease.
cute leukemia in complete remission, chronic myelocytic leukemia
in chronic phase, malignant lymphoma in complete remission,
multiple myeloma in complete remission, myelodysplastic syn-
drome in refractory anemia, and aplastic anemia were deﬁned as
low risk. All others were considered high risk.
Patient was treated with ﬂudarabine-containing chemotherapy be-
fore transplantation.rmation of infection, as described previously. g
B&MTMortality was considered directly attributable to a
loodstream pathogen if the patient died within 7 days
fter the last positive blood culture without any other
robable cause of death. Patients were considered to
ave responded to antibiotics on the basis of decreas-
ng fever (to 38°C) within 96 hours of initiating
herapy with the antibiotic.
nd Points
The aims of this study were (1) to determine the
ncidence of BSI within 100 days of RI-CBT, (2) to
escribe pathogens involved in BSI, (3) to investigate
linical features of BSI, and (4) to identify risk factors
f BSI.
tatistical Analysis
Cumulative incidences of BSI were evaluated by
sing Gray’s method, [26] and death without BSI was
onsidered as a competing risk. Potential confounding
actors considered in the analysis included age, sex,
tem cell dose, HLA disparity, GVHD prophylaxis,
onditioning regimen, regimen-related gut toxicity,
eutrophil count, CMV antigenemia, acute GVHD,
nd the presence of pre-engraftment fever. Propor-
ional hazard modeling was used to evaluate the inﬂu-
nces of these factors on the incidence of BSI: neu-
rophil count, corticosteroid dose, CMV antigenemia,
nd the development of acute GVHD were treated as
ime-dependent covariates. Factors associated with at
east borderline signiﬁcance (P  .10) in univariate
nalyses were subjected to multivariate analysis with
ackward stepwise proportional hazard modeling.
alues of P  .05 were considered statistically signif-
cant.
ESULTS
atient Characteristics and Clinical Outcomes
Patient characteristics are shown in. Table 1 Pri-
ary neutrophil engraftment was achieved by 79 pa-
ients within 100 days of RI-CBT. The median day of
ngraftment was day 20 (range, 11-53 days). Trans-
lant-related mortality occurred in 16 patients (16%)
ithin 30 days of RI-CBT and in 44 patients (43%)
ithin 100 days. Progression of underlying diseases
as not noted in any patients within 30 days of RI-
BT, but it occurred in 13 patients and was respon-
ible for 4 deaths within 100 days. As of October 2004,
he median follow-up of surviving patients was 5.5
onths (range, 4.1-31 months). Overall survival rates
ere 83% at day 30 and 50% at day 100.
Noninfectious pre-engraftment fever [16] devel-
ped in 58 patients. Grade II to IV acute GVHD was
resent in 23 patients, whereas grade III to IV acute
VHD occurred in 18 patients. The median onset of
rade II to IV acute GVHD was day 22 (range, 11-44
431
d
m
p
v
I
p
1
a
C
C
t
d
c
S
(
o
s
p
a
E
A
S
w
d
t
i
O
w
p
p
C
t
o
c
v
MF
d
1
3
T
O
O
P
I
M
P
C
A
R
R
G
*
†
‡
§

¶
#
*
†
‡
H. Narimatsu et al.
4ays). Corticosteroids, comprising prednisolone or
ethylprednisolone 0.2 mg/kg/d, were used in 60
atients for underlying diseases, pre-engraftment fe-
ers, engraftment syndrome, or acute GVHD.
ncidence of BSI
BSI developed within 100 days of RI-CBT in 32
atients. The median onset of BSI was day 15 (range,
-96 day). The cumulative incidence of BSI was 25%
t day 30 and 32% at day 100 (Figure 1).
linical Features of BSI
The clinical features of BSI are shown in Table 2.
ausative Organisms
Gram-positive bacteremia was identiﬁed in 23 pa-
ients. Causative organisms included Staphylococcus epi-
ermidis (n  11), Staphylococcus aureus (n  6), Entero-
occus faecium (n  4), Enterococcus faecalis (n  4),
treptococcus mitis (n  1), Stomatococcus mucilaginosus
n  1), Streptococcus agalactiae (n  1), Streptococcus
ralis (n  1), Streptococcus sanguis (n  1), Streptococcus
pecies (n  1), and gram-positive rods (n  1).
Gram-negative bacteremia was observed in 16
atients. Causative organisms included Pseudomonas
eruginosa (n 12), Stenotrophomonas maltophilia (n 4),
nterobacter cloacae (n  2), Escherichia coli (n  2), and
lcaligenes xylosoxidans (n  1).
Multiple pathogens were cultured in 14 patients.
taphylococcus aureus indicative of methicillin resistance
as cultured in 6 patients. Pseudomonas aeruginosa in-
icative of multidrug resistance was cultured in 3 pa-
ients. Fungemia due to Trichosporon beigelii was noted
n 1 patient.
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igure 1. Cumulative incidence of BSI. BSI developed within 100
ays in 32 patients. The median onset of BSI was day 15 (range,
-96 days). The cumulative incidence of BSI was 25% at day 30 andw2% at day 100. BSI indicates bloodstream infection.
32ther Infectious Complications
CMV antigenemia developed in 54 patients (53%)
ithin 100 days, and 53 were successfully treated with
reemptive ganciclovir or foscarnet. The remaining
atient died of duodenal perforation due to duodenum
MV enterocolitis ulceration, despite prior preemp-
ive therapy. Another 2 patients died within 100 days
f RI-CBT because of other fatal infectious compli-
ations, namely, miliary tuberculosis (n  1) and in-
asive aspergillosis (n  1).
ortality of BSI
Within 100 days after RI-CBT, 25 patients (84%)
able 2. Patient Characteristics at Onset of BSI and Treatment
utcomes
Variable Data
nset, day (range) 15 (1-96)
Before engraftment/after engraftment 24/8
atient status (febrile/afebrile) 31/1*
nserted catheter at onset day (central/
peripheral) 24†/8‡
edian neutrophil count at onset day (/L) 0
resence of grade II-IV acute GVHD at
onset day (yes/no) 0/32
orticosteroid use*‡ at onset day
(yes/no)§ 8/24
ntibiotic use for bacterial infection at
onset day†
Fluoroquinolones 12
-Lactams 8
Carbapenems 7
Vancomycin 5
Aminoglycosides 2
None 2
esponse to antibiotics
(responded/nonresponded) 7/24¶,#,**,††
eccurence of BSI 3‡‡
VHD indicates graft-versus-host disease.
Blood culture was obtained because of persistent low-grade fever.
Causative organisms included gram-negative (n  21) and gram-
positive (n  11) bacteria.
Causative organisms included gram-negative (n  5) and gram-
positive (n  3) bacteria and Trichosporon beigelii (n  1).
Use of predonisolone or methylpredonisolone 0.2 mg/kg/d.
Six patients responded before engraftment.
Causative organisms included Pseudomonas aeruginosa (n  9);
Staphylococcus aureus (n  5); Staphylococcus epidermidis (n  5);
Stenotrophomonas maltophilia (n 4); Enterococcus faecium (n 4);
Streptococcus agalactiae (n  1); Stomatococcus mucilaginosus (n  1);
Trichosporon beigelii (n  1); Enterococcus faecalis (n  1); Alcali-
genes xylosoxidans (n  1); Enterobacter cloacae (n  1); Escherichic
coli (n  1); and -Streptococcus (n  1).Six patients responded
before engraftment.
Four patients did not recoverafter engraftment.
*Fever subsided 16 days after onset in 1 patient. The remaining 3
patients recovered after engraftment.
†Twenty-one patients died.
‡Causative organisms were not identical in those patients.ith deﬁnitive BSI died because of sepsis (n  12),
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Bneumonia (n  5), disease progression (n  2), in-
estinal hemorrhage (n  2), acute GVHD (n  2),
hrombocytic microangiopathy (n  1), and invasive
spergillosis (n  1). BSI was directly associated with
eath in 8 patients (mortality rate, 25%).
Mortality rates were 13% for gram-positive bac-
eria and 38% for gram-negative bacteria. Organisms
ausing fatal BSI included Pseudomonas aeruginosa
n  5), Stenotrophomonas maltophilia (n  2), Staphy-
ococcus aureus (n  2), Alcaligenes xylosoxidans (n  1),
nd gram-positive rods (n  1).
isk Factors of BSI
Univariate analysis failed to identify any signiﬁ-
ant risk factors (Table 3), and multivariate analysis
as therefore not conducted.
ISCUSSION
This study identiﬁed BSI as a signiﬁcant compli-
ation after RI-CBT. The incidence of BSI within 100
ays of transplantation was 32% after RI-CBT. Little
nformation is available on BSI after CBT, but Saavedra
t al. [17] reported that the incidence of BSI was 55%
fter CBT with myeloablative regimens. The BSI in-
idence after RI-CBT is probably lower than that after
BT with myeloablative regimens. The incidence in
his study was lower than that after CBT with my-
loablative regimens. Although previous studies on
BT have mostly involved pediatric patients,
7-9,19,27,28] subjects in this study were elderly and
t high risk of BSI. Reducing the intensity of condi-
ioning regimens in CBT can probably decrease the
isk of infection, similar to the situation in bone mar-
ow and peripheral blood stem cell transplantation.
5,6,29,30] The incidences of BSI were 20% to 30%
fter reduced-intensity stem cell transplantation
RIST) from an HLA-identical related donor, [5,6]
hich were comparable to our result of BSI incidence
fter RI-CBT. The incidences after myeloablative
llo-SCT from a matched sibling or matched unre-
ated donor were slightly higher (40%-50%). [6,31]
he rate of fatal bacterial infection after RI-CBT is
omparable to that of 12% after haploidentical T
ell–depleted peripheral blood transplantation with
yeloablative preparative regimens. [32]
BSI after RI-CBT tends to develop early after
ransplantation and to be followed by severe clinical
ourses compared with that after RIST. The median
nset of BSI was day 15, and 84% of patients died
ithin 100 days of RI-CBT in this study, whereas a
edian onset of day 44 and death in 13% of patients
ithin day 100 were reported in RIST with marrow or
eripheral blood stem cells. [6] The early onset and
everity of BSI are similar to those seen in tuberculosis
fter RI-CBT. [33] These trends can be explained by C
B&MTfew basic mechanisms. One is the delayed engraft-
ent leading to prolonged neutropenia after RI-CBT
ompared with that after RIST of peripheral blood
tem cells. [7-9,16,19,27,28,34-36]
Because neutrophils represent the major protec-
ive factor against bacterial infections, prolonged neu-
ropenia could be expected to contribute to the severe
SI. Another contributing factor is the fact that im-
une cells in cord blood are mostly naive and carry
ow protective effects against infection. [37] Because
ord blood does not contain antigen-exposed cells
uring early-phase immune recovery with peripheral
xpansion of mature T and B lymphocytes transferred
ith the graft, immune reconstitution is slow, and this
eads to an increased risk of infectious complications.
onditioning regimens containing purine analogs and
otal body irradiation are so immunosuppressive that
atients remain highly immunosuppressed in the early
hase after RI-CBT.
In contrast to the high incidence of early infec-
ions, the incidence of late infections after engraft-
ent is not high in RI-CBT. In this study, fatal fungal
nfection developed in only 1 patient. This is in sharp
ontrast to RIST with peripheral blood. [37,38] The
ow incidence of late infections may be associated with
he low incidence of GVHD after CBT, although
urther clinical studies are necessary. Advances in pro-
hylaxis against fungal infections have decreased the
ncidence of these during neutropenia and have re-
ulted in a shift in onset to the time at which GVHD
ommonly develops. [38-40] Risk factors for fungal
nfection during this period include GVHD and use of
teroids. The low frequency of both factors after RI-
able 3. Univariate and Multivariate Analyses for the Risk of BSI
nset
Univariate Factor
Relative Risk
(95% CI)
P
Value
ge 1.01 (0.99-1.04) .42
ex 1.48 (0.72-3.02) .29
nfused cell dose 0.88 (0.51-1.52) .64
nfused cell dose (CD34 cells) 0.98 (0.54-1.78) .95
LA match
5/6 0.38 (0.039-3.69) .40
4/6 0.62 (0.084-4.59) .64
VHD prophylaxis
(cyclosporine versus
tacrolimus) 0.90 (0.35-2.34) .83
onditioning regimen (melphalan
versus busulfan) 0.37 (0.05-2.69) .32
re-engraftment fever 1.91 (0.95-3.84) .071*
ut RRT 0.91 (0.32-2.59) .85
eutrophil count 1.18 (0.87-1.59) .30
MV antigenemia 1.22 (0.38-3.92) .74
teroid dose 43.1 (0.084-22300) .24
rade II-IV acute GVHD 1.71 (0.44-6.70) .44
RT indicates regimen-related toxicity; CMV, cytomegalovirus;
GVHD, graft-versus-host disease; CI, conﬁdence interval.BT is probably associated with the reduced inci-
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4ence of late infections. The overall incidence of BSI
fter RI-CBT is comparable to that after RIST of
one marrow and peripheral blood stem cells, where
arly infections have decreased and late ones have
ncreased.
Identiﬁcation of high-risk patients and intense in-
ection management are important if treatment out-
omes for BSI after RI-CBT are to be improved.
dentiﬁcation of risk factors for BSI is required to
etermine therapeutic strategies. In this study, none of
he conventional risk factors for BSI after allo-SCT
3,5,41,42] was signiﬁcantly associated with BSI. Our
tudy might not have statistical power because of the
mall sample size, but the mechanisms of BSI devel-
pment after RI-CBT may differ from those after
onventional allo-SCT. Further studies are warranted.
The organisms causing BSI after RI-CBT are sim-
lar to those responsible for infection after conven-
ional allo-SCT and RIST. The frequency of coagu-
ase-negative staphylococci was high, and 58% of
ausative bacteria were gram-positive cocci. Gram-
egative bacteria were resistant to treatments and
ere associated with high mortality, but they were less
ommon than gram-positive bacteria. Multiple drug–
esistant Pseudomonas aeruginosa caused most of the
atal gram-negative BSIs. Pseudomonas species are
nown as the cause of severe BSI after allo-SCT. [3]
ecause most patients in our study had been admin-
stered antibiotics during previous chemotherapies,
long with prophylactic ﬂuoroquinolones after RI-
BT, multiple drug–resistant Pseudomonas species had
robably colonized. Evaluation for Pseudomonas spe-
ies colonization before RI-CBT may aid in the iden-
iﬁcation of patients at high risk of BSI. Prophylactic
dministration of antibiotics to which the cultured
seudomonas species is sensitive might help to prevent
SI. We are planning a prospective study to investi-
ate the usefulness of surveillance blood culture to
dentify patients at high risk of BSI.
We used ﬂuoroquinolones as prophylaxis in RI-
BT, because antibacterial prophylaxis with ﬂuoro-
uinolones has reduced the frequency of gram-nega-
ive bacteremia. [43] We are also concerned that
outine use of ﬂuoroquinolones may lead to the evo-
ution of antibiotic-resistant bacteria, [44] and there is
o evidence about a survival beneﬁt with prophylactic
uoroquinolones. Careful clinical studies are needed
n the use of ﬂuoroquinolones.
Although this study provided novel information
n BSI after RI-CBT, the limitations of the study
ust be considered. Unrecognized biases might have
ffected the results of this small, retrospective study.
ecause all patients received prophylactic antibiotics,
he sensitivity of blood cultures would not have
een high. [45] The presence of bacteria that are
ifﬁcult to isolate in blood cultures can also be
nderestimated. [46]
34In conclusion, this study showed that BSI is a
igniﬁcant complication after RI-CBT. BSI before
ngraftment is a signiﬁcant problem of RI-CBT that
eads to a high mortality rate within 100 days of
I-CBT. Appropriate management thus needs to be
stablished to improve outcomes after RI-CBT. Iden-
iﬁcation of high-risk patients is crucial. Because most
SIs develop during neutropenia, modiﬁcation of con-
itioning regimens to attenuate mucositis, promotion of
ngraftment by using multiple cord blood units, and
rophylactic granulocyte infusions may prove helpful.
ppropriate use of antibiotics before RI-CBT is neces-
ary to prevent the emergence of resistant bacteria. Fur-
her prospective clinical studies are awaited to evaluate
he efﬁcacy of these proposed strategies.
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